Mr Mrs Miss Ms Dr Other

Ms
Sian
Hope

Senior IP Solicitor

London Office

Law

Telephone. +44(0) 207 776 5111
Email. shope@hgf-law.com
Vcard
Linkedin

Experience

Sian has expertise in IP litigation and non-contentious IP matters. She is passionate about life sciences and has primarily advised pharmaceutical clients across all stages of patent litigation.

In particular, Sian advises pharmaceutical and healthcare clients in relation to UK High Court and Court of Appeal matters (notably the high-stakes UK rivaroxaban (Xarelto) patent proceedings), as well as pan-European and UPC matters. She also assists clients in enforcing their soft-IP rights particularly in the retail sector.

She completed a BSc and LLB at Monash University in Australia, is a member of the NSW Law Society and is a Registered Foreign Lawyer in the UK.

Specialisms

Industries

Services

Qualifications

Solicitor

Other
Australia

BSC

Genetics & Molecular Biology

LLB

(Honours)

Publications

A leading case - beware sequence errors in patent claims

View publication online

UPC on Doctrine of Equivalents

View publication online

UPC stakes claim for wide-reaching long-arm jurisdiction for European patents

View publication online

Court of Appeal Confirms No Second Medical Use SPCs in UK

View publication online

A leading case – beware sequence errors in patent claims

View publication online

UPC on Doctrine of Equivalents

View publication online

UPC stakes claim for wide-reaching long-arm jurisdiction for European patents

View publication online

Court of Appeal Confirms No Second Medical Use SPCs in UK

View publication online

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article
Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us